Note 13 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2023	Mar. 08, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Contract with Customer, Performance Obligation Satisfied in Previous Period						$ 2,200	$ 19,800
Accrued Expense, Payor Overpayment Reimbursement, Liability			$ 4,900	$ 4,900		4,900		$ 3,100
Revenue from Contract with Customer, Excluding Assessed Tax				173,632	$ 178,595	529,504	681,591
BARDA Agreement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 24,100	5,500		12,800
Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 50,000	$ 50,000
Rayaldee [Member]
Contract with Customer, Liability, Revenue Recognized				5,800	7,300	19,900	21,700
Revenue from Contract with Customer, Excluding Assessed Tax				15,865	16,090	49,447	47,940
Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				13,218	6,246	34,272	165,938
Transfer of Intellectual Property and Other [Member] | Milestone Payments [Member] | Pfizer Inc. [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 7,000	$ 4,900	$ 18,900	$ 11,800
Transfer of Intellectual Property and Other [Member] | Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member]
Revenue from Contract with Customer, Excluding Assessed Tax								7,000
Transfer of Intellectual Property and Other [Member] | Development and License Agreement [Member] | NICOYA Macau Limited [Member]
Revenue from Contract with Customer, Excluding Assessed Tax								$ 2,500